IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.744
AS - Asia 1.932
EU - Europa 899
SA - Sud America 445
Continente sconosciuto - Info sul continente non disponibili 173
AF - Africa 46
OC - Oceania 7
Totale 6.246
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.645
SG - Singapore 861
IT - Italia 459
CN - Cina 458
BR - Brasile 342
VN - Vietnam 218
IN - India 186
DE - Germania 100
SE - Svezia 100
GB - Regno Unito 79
CA - Canada 62
BD - Bangladesh 45
HK - Hong Kong 45
AR - Argentina 42
FI - Finlandia 34
MX - Messico 22
NL - Olanda 22
EC - Ecuador 20
FR - Francia 20
JP - Giappone 19
EU - Europa 18
RU - Federazione Russa 16
ID - Indonesia 14
RO - Romania 13
UA - Ucraina 13
ES - Italia 12
IQ - Iraq 12
ZA - Sudafrica 12
PK - Pakistan 10
TR - Turchia 10
CL - Cile 9
PY - Paraguay 9
VE - Venezuela 9
AT - Austria 7
CZ - Repubblica Ceca 7
JO - Giordania 7
TW - Taiwan 7
AU - Australia 6
CO - Colombia 6
UZ - Uzbekistan 6
EG - Egitto 5
IR - Iran 5
MA - Marocco 5
NP - Nepal 5
PE - Perù 5
PL - Polonia 5
SC - Seychelles 5
SA - Arabia Saudita 4
TN - Tunisia 4
AZ - Azerbaigian 3
CH - Svizzera 3
CR - Costa Rica 3
DZ - Algeria 3
KE - Kenya 3
KZ - Kazakistan 3
MY - Malesia 3
PA - Panama 3
UY - Uruguay 3
BW - Botswana 2
CG - Congo 2
DO - Repubblica Dominicana 2
GR - Grecia 2
GT - Guatemala 2
KR - Corea 2
PH - Filippine 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
LB - Libano 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.092
Salva come PNG Salva come JPEG
Città #
San Jose 526
Singapore 292
Ashburn 244
Chandler 230
Dallas 169
Santa Clara 148
Council Bluffs 138
Hefei 126
Bengaluru 123
Milan 119
Lawrence 106
Princeton 106
Ho Chi Minh City 89
Beijing 75
Munich 59
Wilmington 58
Chicago 55
Catanzaro 49
London 49
Hong Kong 44
Des Moines 40
New York 38
Hanoi 37
Ottawa 28
São Paulo 28
Los Angeles 27
Turku 23
Brooklyn 18
Rome 16
Phoenix 15
Guangzhou 13
Montreal 13
Naples 13
Redwood City 13
Pune 12
Tokyo 12
Boardman 11
Da Nang 11
Helsinki 11
Rio de Janeiro 11
San Francisco 11
Shanghai 11
Haiphong 10
Redmond 10
The Dalles 10
Porto Alegre 9
Toronto 9
Biên Hòa 8
Columbus 8
Amman 7
Brasília 7
Charlotte 7
Guayaquil 7
Buffalo 6
Can Tho 6
Chennai 6
Cosenza 6
Horia 6
Jiaxing 6
Leawood 6
Manchester 6
Mexico City 6
Mountain View 6
Tashkent 6
Timisoara 6
Ahmedabad 5
Atlanta 5
Augusta 5
Baghdad 5
Belo Horizonte 5
Kulgam 5
Lima 5
Olomouc 5
Orem 5
Parma 5
Quito 5
Reggio Calabria 5
Salvador 5
San Nicola Manfredi 5
Zhengzhou 5
Ankara 4
Asunción 4
Bari 4
Berlin 4
Birigui 4
Curitiba 4
Dhaka 4
Florianópolis 4
Goiânia 4
Hanover 4
Jakarta 4
Miami 4
Norwalk 4
Paris 4
San Antonio 4
Santiago 4
Settingiano 4
Stockholm 4
Taoyuan District 4
Thái Bình 4
Totale 3.536
Salva come PNG Salva come JPEG
Nome #
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations 171
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 146
miR-22 suppresses DNA ligase III addiction in multiple myeloma 108
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 95
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 83
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 79
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 79
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 78
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 77
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 76
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 76
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. 74
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 74
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 74
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 72
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 70
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 69
Enlarging the clinical spectrum of chorea-acanthocytosis 66
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 66
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia 65
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 65
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 64
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 64
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 63
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 63
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype 62
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 62
Mir-221/222 are promising targets for innovative anticancer therapy 61
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. 60
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 60
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 59
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 58
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 58
Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: Insights fromthe EYESHOT study 57
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 57
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 56
Role of Nucleophosmin in embryionic development and tumorigenesis 56
The non-coding RNA landscape of plasma cell dyscrasias 56
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 55
Mycosis fungoides and gastric t-cell lymphoma: A case report 55
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 53
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 52
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 52
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 51
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 51
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 50
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 50
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 49
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 49
Dendritic cells have the option to express IDO-mediated suppression or not 49
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and adaptive Immunity 49
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 49
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 49
Daunorubicina liposomiale in ematologia 48
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 48
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 47
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 46
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 46
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 45
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 45
CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues 45
Immunologic microenvironment and personalized treatment in multiple myeloma 44
Mouse models of Multiple Myeloma: technologic platforms and perspectives 43
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 43
Translational Studies on the Bone Marrow Microenvironment in Multiple Myeloma: Experimental Models and Emerging Therapeutical Strategies 43
null 43
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 42
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management? 42
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 42
Osteonecrosis of the Jaw Prevention and Management in Modern Oncology 42
Emerging Role of MicroRNAs in the Pathophysiology of Immune System 41
Multiple myeloma-related bone disease: state-of-art and future treatments 41
Multiple Myeloma Cells downregulatemiR-29b in dendritic cells to promote a tumor permissive inflammatory microenvironment and immune escape 40
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 40
Molecular Targets for the Treatment of Multiple Myeloma 40
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells 38
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 38
Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report 37
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress 37
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 37
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 37
CFD analysis of different arterial cannulation site during Heart Surgery with Cardioplumnonary Bypass 37
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 37
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 36
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 36
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 36
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 36
Targeting miR-21 in bone marrow stromal cells restores RANKL/OPG ratio within multiple myeloma microenvironment 36
Non-Coding RNAs in multiple myeloma bone disease pathophysiology 36
MicroRNAs in multiple myeloma and related bone disease 36
Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients 35
Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia 35
Whole Body Magnetic Resonance and CT/PET in patients with multiple myeloma at staging and after treatment: personal experience in a longitudinal study 34
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches 33
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients 32
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 32
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 31
miR-29b targets HDAC4 and mediates activity of HDAC inhibitors in multiple myeloma cells 31
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 30
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma 30
Totale 5.371
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.628
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.628
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022310 0 4 4 72 36 17 10 58 25 30 48 6
2022/2023723 223 37 33 46 69 54 4 49 103 38 51 16
2023/2024325 74 44 23 18 26 87 8 7 2 9 13 14
2024/20251.375 190 93 67 69 96 167 30 40 142 69 144 268
2025/20263.010 142 280 315 583 308 109 399 178 357 209 83 47
2026/2027189 25 164 0 0 0 0 0 0 0 0 0 0
Totale 6.246